

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Health Technology Appraisal**

**Review of NICE Technology Appraisal Guidance No.27, Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis**

**List of organisations invited to comment on the review proposal**

- Arthritis and Musculoskeletal Alliance (prev known as the British League Against Rheumatism)
- Arthritis Care
- Arthritis Research Campaign
- Ashford PCT
- Boehringer Ingelheim Ltd
- Bolton PCT
- British Health Professionals in Rheumatology
- British Institute of Musculoskeletal Medicine
- British National Formulary
- British Society for Rheumatology
- British Society of Gastroenterology
- Chartered Society of Physiotherapy
- Cochrane Upper Gastro-intestinal and Pancreatic Diseases Group
- Department of Health
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Merck Sharp and Dohme Ltd
- National Collaborating Centre for chronic conditions
- National Public Health Service for Wales
- National Rheumatoid Arthritis Society
- NHS Confederation
- NHS Purchasing and Supplies Agency
- NHS Quality Improvement Scotland
- Novartis Pharmaceuticals Ltd
- Pfizer Ltd
- Primary Care Rheumatology Society
- Royal Association for Disability & Rehabilitation
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Physicians
- Royal Pharmaceutical Society
- Shire Pharmaceuticals Ltd
- Welsh Assembly Government